Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Member Organization News

Ash Stevens to Make API For Takeda's New Oral Blood Cancer Drug

Wednesday, November 25, 2015   (0 Comments)
Share |

The US FDA has cleared Ash Stevens to make the API for Takeda's new multiple myeloma drug Ninlaro, which is the first oral proteasome inhibitor to be approved in the country.

 

The US contract manufacturing organization (CMO) will produce the active pharmaceutical ingredient (API) - ixazomnib - at it's facility in Riverview, Michigan.

Read More

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal